Why do some people respond to peptides and others don’t?

Even effective drugs produce a range of responses. In STEP 1, semaglutide caused substantial average weight loss, but the average was not everyone’s result. Baseline biology, the condition being treated, exposure, treatment duration, and other care can affect what happens. A dose on a label also does not guarantee the same actual exposure, particularly when product quality or absorption is uncertain.[1][2]

For BPC-157, the bigger problem is that we lack strong controlled human evidence defining a typical healing response. A friend’s report that a torn labrum healed in six weeks may describe less pain rather than documented structural repair. Diagnosis, rehabilitation, natural recovery, other treatments, and expectations can all differ. A small uncontrolled knee-pain report cannot tell us what percentage of comparable patients would benefit or why someone would not.[3]

Start by defining a measurable outcome and timeframe, then ask whether the study actually measured that outcome in a comparable population. Pain scores, strength, imaging findings, and return to activity are different endpoints. Claims that a nonresponse proves “bad receptors,” insufficient dosing, or a need to stack more compounds are usually speculative without measurements and controlled comparisons.[1][3]